3D Bioprinting Builds Beating Heart Tissue With Programmed Architecture
A 2025 review maps how 3D bioprinting platforms, bioinks, and cell strategies are converging to engineer functional heart tissue for repair and disease modeling.
Summary
This comprehensive 2025 review from the University of British Columbia examines how 3D bioprinting is advancing cardiac tissue engineering beyond conventional casting methods. The authors compare four major printing platforms—jetting, stereolithography/DLP, extrusion, and volumetric—and evaluate their trade-offs for cardiac applications. Bioink strategies are shifting from single natural polymers toward hybrid formulations combining bioactivity with synthetic tunability, including conductive and shape-morphing components. Cell sources such as iPSC-derived cardiomyocytes and co-culture strategies are reviewed. Applications span cardiac patches, chambered constructs, and organoids. The review concludes that bioprinting's spatial precision in programming cell alignment, stiffness, and vascular pathways positions it as a leading strategy for creating in vivo-like heart tissues.
Detailed Summary
Heart disease remains a leading cause of death globally, and the adult heart has virtually no meaningful intrinsic regenerative capacity. After myocardial infarction, lost cardiomyocytes are replaced by non-contractile scar tissue, permanently impairing pump function. Conventional tissue engineering approaches—2D monolayers and 3D casting—suffer from heterogeneous cellularization, slow electromechanical maturation, and inadequate vascularization. Three-dimensional bioprinting offers a compelling solution by depositing cells and biomaterials in predefined, programmable architectures that can replicate the anisotropy, stiffness, vascular channels, and electrical coupling of native myocardium.
This review systematically compares four major bioprinting modalities. Jetting-based approaches (inkjet, laser-assisted, and electrohydrodynamic jet) offer contactless, high-resolution deposition but are generally limited to thin constructs (~50–500 µm) and narrow bioink viscosity ranges, constraining their current cardiac utility. Stereolithography and digital light processing (DLP) enable complex geometries and 4D shape-morphing patches—for example, constructs that autonomously curve to match cardiac surfaces—though photoinitiator cytotoxicity requires careful management. Extrusion-based bioprinting dominates current cardiac tissue engineering practice due to its versatility, cost-effectiveness, and capacity to align cells through shear stress during deposition; innovations like melt-electrowriting scaffolds and pre-formed anisotropic organ building blocks markedly improve mechanical support and electromechanical maturation. Volumetric bioprinting represents an emerging frontier capable of fabricating centimeter-scale constructs in seconds, with potential to overcome the thickness and speed bottlenecks of layer-by-layer methods.
Bioink design is evolving rapidly. The trend is toward natural–synthetic hybrid formulations: naturally derived materials such as decellularized extracellular matrix (dECM), collagen, and fibrin provide bioactivity and cell adhesion cues, while synthetic components such as GelMA, PEG, and methacrylated hyaluronic acid (MeHA) contribute mechanical tunability. Conductive additives (carbon nanotubes, graphene, PEDOT) are incorporated to enhance electrical coupling between cardiomyocytes, and shape-morphing materials enable 4D constructs that respond to environmental stimuli post-printing. Suspended/embedded printing strategies in support baths (e.g., Pluronic, gelatin slurry) allow low-viscosity, biologically favorable inks to maintain structural fidelity.
On the cell side, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are the dominant source, offering patient specificity and scalability, though their relative immaturity compared to adult cardiomyocytes remains a challenge. Co-culture with cardiac fibroblasts, endothelial cells, and smooth muscle cells enhances maturation, vascularization, and structural organization. Applications now extend from simple cardiac patches and muscle strips to chambered heart constructs with inflow/outflow tracts and self-organizing organoids capable of recapitulating disease phenotypes.
Despite rapid progress, critical limitations persist. Achieving clinically relevant tissue thickness with adequate internal vascularization remains unsolved. The immaturity of iPSC-CMs—displaying fetal rather than adult electromechanical properties—limits both in vitro predictive accuracy and in vivo integration potential. Bioink standardization and printing parameter reproducibility across laboratories are lacking. The review identifies volumetric bioprinting and advanced maturation protocols (mechanical and electrical stimulation bioreactors, metabolic switching) as among the most promising near-term directions.
Key Findings
- Extrusion-based bioprinting dominates cardiac tissue engineering; pre-formed anisotropic building blocks significantly boost contractile force output.
- Natural–synthetic hybrid bioinks combining dECM or collagen with GelMA or PEG balance bioactivity with mechanical tunability for cardiac constructs.
- Conductive additives (carbon nanotubes, graphene) integrated into bioinks enhance electrical coupling and cardiomyocyte synchrony.
- DLP and stereolithography enable 4D shape-morphing cardiac patches that autonomously conform to heart surface curvature.
- iPSC-CM immaturity and insufficient internal vascularization remain the primary barriers to clinically translatable bioprinted heart tissues.
Methodology
This is a narrative review article synthesizing published literature on 3D bioprinting for cardiac tissue engineering. The authors compare printing modalities, bioink chemistries, cell sources, and functional characterization readouts across recent experimental studies. No original experimental data were generated; conclusions are drawn from critical appraisal of existing studies.
Study Limitations
As a narrative review, it lacks systematic search methodology or meta-analytic rigor, introducing potential selection bias in study inclusion. Most reviewed studies are proof-of-concept in vitro or small-animal experiments, and long-term in vivo performance data for bioprinted cardiac constructs remain scarce. iPSC-CM immaturity is a pervasive confounder across nearly all cited studies, limiting the physiological relevance of current findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: